WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001030974) MOLECULES TARGETING CD40 WHICH DO NOT ACTIVATE CD40-EXPRESSING CELLS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/030974    International Application No.:    PCT/US2000/041532
Publication Date: 03.05.2001 International Filing Date: 25.10.2000
Chapter 2 Demand Filed:    10.05.2001    
IPC:
A61K 38/16 (2006.01), A61K 38/17 (2006.01), A61K 39/00 (2006.01)
Applicants: TANOX, INC. [US/US]; 10301 Stella Link Road, Houston, TX 77025 (US)
Inventors: CHANG, Nancy; (US)
Agent: MIRABEL, Eric; Tanox, Inc., 10301 Stella Link Road, Houston, TX 77025 (US).
LILJESTRAND, Cheryl, A.; Tanox, Inc., 10301 Stella Link, Houston, TX 77025 (US)
Priority Data:
60/161,281 25.10.1999 US
Title (EN) MOLECULES TARGETING CD40 WHICH DO NOT ACTIVATE CD40-EXPRESSING CELLS
(FR) MOLECULES CIBLANT CD40, N'ACTIVANT PAS LES CELLULES EXPRIMANT CD40
Abstract: front page image
(EN)Disclosed are molecules which are not antibodies which bind to the CD40 antigen but which do not cause proliferation, differentiation or activation of B lymphocytes or other cells carrying the CD40 antigen and can inhibit CD40 ligand induced activation. These molecules target, bind to or interact with a particular epitope on CD40. They are useful for treating autoimmune, cell-mediated and antibody-mediated diseases.
(FR)L'invention concerne des molécules qui ne sont pas de anticorps, et qui se lient avec l'antigène CD40, mais ne provoquent pas de prolifération, de différentiation ou d'activation des lymphocytes B ou d'autres cellules porteuses de l'antigène CD40 et sont capables d'inhiber l'activation induite par le ligand de CD40. Ces molécules ciblent, se lient ou interagissent avec un épitope particulier sur CD40. Elles sont utiles pour traiter les maladies auto-immunes, les maladies à médiation cellulaire et les maladies à médiation d'anticorps.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)